Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells. - Wikidata - wikimedia - TriplyDB

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

http://www.wikidata.org/entity/Q37725751

about

Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery Potential targets for pancreatic cancer immunotherapeutics.An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites.Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice.

P2860

Q36071752-788A5F24-35C1-4BD1-AFC7-659E0F025AD0 Q36110284-9C316AF6-EE88-4167-9D51-559086E06CF0 Q37164976-3A50B50E-5F91-4EF2-96FE-15F0E9DC5EE3 Q37861220-1CE3BFB2-D953-413A-ABA0-3BD5D769DD4E Q38933648-7DE9A269-366C-4F41-8757-D0A9647B3402 Q39555982-953E7858-1ED2-4A82-8434-5CBF8BA97D45

P2860

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

http://www.wikidata.org/entity/Q37725751

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@en

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@nl

type

label

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@en

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@nl

prefLabel

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@en

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@nl

P1433

Q37725751-CC87B23B-ADD5-4623-A5DB-899083D83489

P1476

Q37725751-1E984451-C087-493B-921B-C4294859F6BF

P2093

Q37725751-F4D0D77A-E476-4F6B-A355-277E6DDC3B89

P2860

Q37725751-20503458-8E33-4DB2-A7B6-ED631532ACFD

Q37725751-2DD27AF5-0156-4000-89C2-4BD0D14756F1

Q37725751-3339F7AF-FE3F-473C-82E7-FC76451B6B21

Q37725751-40BE234A-D74F-42A5-B5AF-BD9328FB8BD6

Q37725751-41BD15EB-7F96-4703-9232-9829A1249FDF

Q37725751-52FA62CA-4114-4604-9258-D470D6629CBD

Q37725751-613B5228-295B-4D2A-874D-1D0B284239B7

Q37725751-6F51CC38-1D9F-4560-956E-46A24D49D3F8

Q37725751-864AFB56-CDA4-4C48-9D34-4BBF1D67941B

Q37725751-924EE7BD-6D88-4AF6-94E6-2EFAB9C94472

P2888

Q37725751-FDBFCECD-8F45-4C1E-9783-CD1C99F92C1F

P304

Q37725751-96F58650-614F-45CE-9E75-3FE9FE6C0697

P31

Q37725751-00EE3BE3-2D00-44CE-87FE-E9C7AA79D22F

P356

Q37725751-E83CEBA3-8694-4911-8D31-2C1F8B73884E

P433

Q37725751-D8B1DF96-8E28-4217-BD42-BD1573978209

P478

Q37725751-11AA31CB-56A9-486E-8FF5-4D9A4F0B12D1

P50

Q37725751-F00412C1-FBFA-4371-B8B2-EFD10807B1AE

P577

Q37725751-4A08ACAA-849D-4A89-8857-46074D7060E9

P5875

Q37725751-1929FC32-4C86-4C83-9AB4-209CC5E7716D

P698

Q37725751-4418F02D-DE3D-4000-9693-F7F14FB53FAF

P921

Q37725751-F2BBD377-C1F4-4758-A150-27F9A9566A2A

P356

S00005-010-0074-1

P1433

Archivum Immunologiae et Therapiae Experimentalis

P1476

Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.

@en

P2093

David Marc Davies

http://www.w3.org/2001/XMLSchema#string

P2860

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.

Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity

Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.

Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.

P2888

s00005-010-0074-1

P304

165-178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00005-010-0074-1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43051413

http://www.w3.org/2001/XMLSchema#string

P698

20373147

http://www.w3.org/2001/XMLSchema#string

P921